Title:
ERBB RECEPTOR INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2019/214634
Kind Code:
A1
Abstract:
Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
More Like This:
| WO/2003/022821 | HETEROCYCLE DERIVATIVE HAVING 20−HETE−PRODUCING ENZYME INHIBITORY ACTIVITY |
| WO/2014/019951 | METHODS OF CONTROLLING INSECTS |
| WO/2013/059928 | HIV PROTEASE INHIBITORS |
Inventors:
LI ZHENGTAO (CN)
ZHONG WEI (US)
WANG JIABING (US)
ZENG QINGBEI (CN)
TSUI HONCHUNG (CN)
YANG ZHENFAN (CN)
ZHANG XIAOLIN (CN)
ZHONG WEI (US)
WANG JIABING (US)
ZENG QINGBEI (CN)
TSUI HONCHUNG (CN)
YANG ZHENFAN (CN)
ZHANG XIAOLIN (CN)
Application Number:
PCT/CN2019/085949
Publication Date:
November 14, 2019
Filing Date:
May 08, 2019
Export Citation:
Assignee:
DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D409/12; A61K31/505; A61P35/00
Domestic Patent References:
| WO2003040109A2 | 2003-05-15 | |||
| WO2006092573A1 | 2006-09-08 | |||
| WO2007034144A1 | 2007-03-29 |
Other References:
BERNARD BARLAAM ET AL.: "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 6, 16 February 2008 (2008-02-16), pages 1799 - 1803, XP025694970, DOI: 10.1016/j.bmcl.2008.02.035
T. HIGUCHIV. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM, vol. 14
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
See also references of EP 3814341A4
T. HIGUCHIV. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM, vol. 14
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
See also references of EP 3814341A4
Attorney, Agent or Firm:
JUN HE LAW OFFICES (CN)
Download PDF: